close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invesco Nasdaq Biotechnology ETF (NQ:IBBQ)

26.02 -0.18 (-0.69%)
Official Closing Price Updated: 4:15 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Invesco Nasdaq Biotechnology ETF

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally
Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday. 
Via Stocktwits
Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’
The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease. 
Via Stocktwits
These 4 ETFs Provide Smart Exposure To Intuitive Machines, The New Space Economy
Intutive Machines specializes in lunar missions and sophisticated space technologies. These ETFs are worth looking at. 
Via Benzinga
Topics ETFs
5 Undervalued ETFs To Ride On Powell's Market Optimism
Here are five ETFs from different zones of the market that are currently undervalued and could generate solid returns in a rising stock market. 
Via Talk Markets
Topics ETFs
Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now
A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17. 
Via Stocktwits
Topics Artificial Intelligence
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
Via Benzinga
Topics ETFs
Time For Gilead Sciences-Heavy ETFs?
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
Biotech ETFs Pop On M&A Resurgence
The biopharma industry has seen a recent upswing in mergers and acquisitions (M&A). 
Via Talk Markets
Should You Buy Biotech ETFs Now?
Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today